Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

SEngine Precision Medicine closes Series A

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery.

The Series A2 round was led by the Washington Research Foundation along with Alethea Fulcrum Fund, Vincere Capital Biotech LLC, Bangarang Group, and other unnamed investors.

SEngine, a 2015 spinout from world-renowned Fred Hutchinson Cancer Research Center, is leveraging over two decades of R&D in diagnostics and drug discovery to revolutionize cancer therapies by pre-testing drugs on patient-derived live tumor cells, outside the patient’s body. SEngine utilizes breakthrough science from cancer genomics, robotics, and proprietary algorithms. SEngine’s CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.

SEngine is also utilizing its precision oncology platform to inform drug discovery via strategic collaborations with biopharmaceutical, and pharma companies as well as, top cancer centers such as Dana-Farber and Gustave Roussy, while advancing its own pipeline of novel targeted drugs.

Investor participation was spurred by the continued momentum of SEngine’s platform in both drug discovery and clinical diagnostics. The inclusion of Vincere in this closing represents the beginning of significant partnership, making the PARIS® Test more broadly available through its network of cancer centers.

“We are very appreciative of our investors support and their recognition of the need for more and better personalized treatments,” said SEngine CEO Dr. Carla Grandori. “The power of SEngine’s PARIS® platform to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs will continue to propel SEngine forward.”

“Washington Research Foundation is excited to support SEngine in delivering important advancements in the field of functional precision medicine, especially at this time when patients and oncologists are ever more aware of the value of personalized treatment insights,” said Will Canestaro, PH.D., Managing Director of Washington Research Foundation. “SEngine’s precision oncology platform has and will continue to advance important new therapies and improve patient outcomes. We have been following the team for many years and have been continually impressed by their ability to develop this technology and build a thriving biotech here in Washington State.”

SEngine’s PARIS® test grows a patient’s tumor cells in a lab, then analyzes them to determine the safest and most effective medications. Oncologists can also choose from SEngine’s library of more than 240 small molecule drugs any specific options they want to test on a patient’s tumor.

This round of funding will be used to accommodate the exponential growth SEngine has experienced in the past two years. Focus will be on hiring more exceptional team members and growing lab space in support of continued drug discovery initiatives, biopharmaceutical, and pharmaceutical partnerships, and continued clinical validation of PARIS Test platform.

About PARIS® Test
The PARIS® Test is a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with drug sensitivity testing of patient-derived live cells combined with robotics and proprietary algorithms. SEngine’s CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Cancer derived cells grown in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine